ClinicalTrials.gg
CompletedNCT05503693Updated May 30, 2024

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

A Phase 1 interventional study of AP303 50 μg and AP303 150 μg in Healthy Subjects, sponsored by Alebund Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Alebund Pty Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.

Read the detailed description

The study will consist of 2 parts: Part A is a single ascending doses (SAD) phase enrolling a total of 4 cohorts of healthy subjects; Part B is a multiple ascending doses (MAD) phase enrolling 3 cohorts of healthy subjects. One cohort of Part A will receive AP303 under both fasted and fed conditions to investigate the effect of food.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Safety, Tolerability, Pharmacokinetics, AP303, Healthy Subjects
03

In context

Lead sponsor

Alebund Pty Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects, 18 to 55 years of age, inclusive.
  2. Body Mas index() between 18 to 32 kg/m2 inclusive.
  3. Female subjects of must have a negative pregnancy test result and agree to use highly effective consisting of two forms of birth control
  4. Subjects and their partners of childbearing potential must use two medically approved methods of contraception and the subjects should refrain from sperm/egg donation for the duration of the study and for 3 months after drug administration

Exclusion criteria

Exclusion Criteria:

  1. Pregnant (positive pregnancy test) or lactating women, and male subjects with partners who are or plan to be pregnant or lactating.
  2. History or symptoms of any gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, ophthalmologic, hematological or allergic disease, metabolic disorder, cancer or cirrhosis.
  3. People with a history of specific allergies, or allergic conditions or known allergies to any ingredient of the medicinal product (IMP).
  4. History of having received or currently receiving any systemic anti-neoplastic or immune-modulatory treatment ≤ 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
  5. Positive test at screening of any of the following: (HBsAg), (HCVAb) or (HIV Ab).
  6. Received an investigational drug within 30 days or 5 xT1/2 whichever is longer prior to the first dose of our study for small molecule; or within 90 days or 5 x T1/2 whichever is longer prior to the first dose of our study drug; or device study within 90 days prior to screening or more than 4 times per year.
  7. History of drug and/or alcohol abuse or addiction.
  8. Use of >5 cigarettes or equivalent nicotine-containing product per day.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    AP303

    AP303

    Drug: AP303 50 μg · Drug: AP303 150 μg · Drug: AP303 300 μg · Drug: AP303 600 μg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo 50 μg · Drug: Placebo 150 μg · Drug: Placebo 300 μg · Drug: Placebo 600 μg

Interventions

06

What researchers measure

Primary outcomes

  1. Single Dose and Food Effect Safety Outcome Measures

    Incidence and severity of adverse events (AEs), laboratory, ECG, and vital sign changes

    Time frame: From baseline to Day 14 (Day 29 for Food Effect)

  2. Multiple Dose Safety Outcome Measures

    Incidence and severity of AEs, laboratory, ECG, and vital sign changes.

    Time frame: From baseline to Day 28

  3. Cmax after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  4. Tmax after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  5. AUC0-last after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  6. AUC0-inf after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  7. t1/2 after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  8. CL/F after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  9. Ae and CLR (if warranted) after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  10. V/F after single dose

    PK characteristics after single dose

    Time frame: Pre-dose to 96 hours post-dose

  11. Cmax after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  12. Tmax after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  13. AUC0-τ after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  14. Cav after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  15. t1/2 after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  16. Rac after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  17. Ae and CLR (if warranted) after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  18. V/F after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose to 12 hours post dose on Day 1; pre-dose to 96 hours post-dose on Day 14

  19. Ctrough after multiple dose

    PK characteristics after multiple dose

    Time frame: Pre-dose on Days 2, 3, 4, 5, 7, 12, and 13

Secondary outcomes

  1. Effect of Food on the single dose Cmax

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  2. Effect of Food on the single dose Tmax

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  3. Effect of Food on the single dose AUC0-last

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  4. Effect of Food on the single dose AUC0-inf

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  5. Effect of Food on the single dose t1/2

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  6. Effect of Food on the single dose CL/F

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  7. Effect of Food on the single dose Ae and CLR (if warranted)

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

  8. Effect of Food on the single dose V/F

    Effect of food on the single dose PK

    Time frame: Pre-dose to 96 hours post-dose

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Aug 17, 2022
StartActual
Dec 6, 2022
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 21, 2023
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05503693
Lead sponsor
Alebund Pty Ltd
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Dec 6, 2022
Primary completion
Jul 21, 2023
Completion
Jul 21, 2023
Last update
May 30, 2024

Study contacts

Sam Francis, Doctor
principal investigator · Nucleus Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP303

Start the discussion